A study is being conducted to understand the effectiveness of ALXN2050 compared with placebo in the treatment of generalized MG (gMG) based on improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score.
Age & Gender
- 18 years ~ 99 years
- Male, Female, Gender Inclusive
Study Interest
- Brain, Head, and Nervous System
Status: Open